Literature DB >> 17400299

Regulation of firing of dopaminergic neurons and control of goal-directed behaviors.

Anthony A Grace1, Stan B Floresco, Yukiori Goto, Daniel J Lodge.   

Abstract

There are several brain regions that have been implicated in the control of motivated behavior and whose disruption leads to the pathophysiology observed in major psychiatric disorders. These systems include the ventral hippocampus, which is involved in context and focus on tasks, the amygdala, which mediates emotional behavior, and the prefrontal cortex, which modulates activity throughout the limbic system to enable behavioral flexibility. Each of these systems has overlapping projections to the nucleus accumbens, where these inputs are integrated under the modulatory influence of dopamine. Here, we provide a systems-oriented approach to interpreting the function of the dopamine system, its modulation of limbic-cortical interactions and how disruptions within this system might underlie the pathophysiology of schizophrenia and drug abuse.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17400299     DOI: 10.1016/j.tins.2007.03.003

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  421 in total

Review 1.  Dopamine tunes prefrontal outputs to orchestrate aversive processing.

Authors:  Caitlin M Vander Weele; Cody A Siciliano; Kay M Tye
Journal:  Brain Res       Date:  2018-12-01       Impact factor: 3.252

2.  The effects of background white noise on memory performance in inattentive school children.

Authors:  Göran B W Söderlund; Sverker Sikström; Jan M Loftesnes; Edmund J Sonuga-Barke
Journal:  Behav Brain Funct       Date:  2010-09-29       Impact factor: 3.759

3.  Use of siRNA in knocking down of dopamine receptors, a possible therapeutic option in neuropsychiatric disorders.

Authors:  Mohammad-Reza Noori-Daloii; Majid Mojarrad; Ali Rashidi-Nezhad; Majid Kheirollahi; Ali Shahbazi; Mehdi Khaksari; Asghar Korzebor; Ali Goodarzi; Maryam Ebrahimi; Ali Reza Noori-Daloii
Journal:  Mol Biol Rep       Date:  2011-06-03       Impact factor: 2.316

4.  A kinesin signaling complex mediates the ability of GSK-3beta to affect mood-associated behaviors.

Authors:  Jing Du; Yanling Wei; Lidong Liu; Yun Wang; Rushaniya Khairova; Rayah Blumenthal; Tyson Tragon; Joshua G Hunsberger; Rodrigo Machado-Vieira; Wayne Drevets; Yu Tian Wang; Husseini K Manji
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

5.  Shifting pharmacology of nicotine use and withdrawal: breaking the cycle of drug abuse.

Authors:  Thibaut Sesia; Anthony A Grace
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-03       Impact factor: 11.205

Review 6.  Virogenetic and optogenetic mechanisms to define potential therapeutic targets in psychiatric disorders.

Authors:  Ming-Hu Han; Allyson K Friedman
Journal:  Neuropharmacology       Date:  2011-09-17       Impact factor: 5.250

Review 7.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

8.  Age-Related Trajectories of Functional Coupling between the VTA and Nucleus Accumbens Depend on Motivational State.

Authors:  Vishnu P Murty; Hemali Shah; David Montez; Will Foran; Finnegan Calabro; Beatriz Luna
Journal:  J Neurosci       Date:  2018-07-20       Impact factor: 6.167

9.  Tectonigral projections in the primate: a pathway for pre-attentive sensory input to midbrain dopaminergic neurons.

Authors:  Paul J May; John G McHaffie; Terrence R Stanford; Huai Jiang; M Gabriela Costello; Veronique Coizet; Lauren M Hayes; Suzanne N Haber; Peter Redgrave
Journal:  Eur J Neurosci       Date:  2009-01-17       Impact factor: 3.386

Review 10.  Hippocampal dysfunction and disruption of dopamine system regulation in an animal model of schizophrenia.

Authors:  Daniel J Lodge; Anthony A Grace
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.